MICHAEL WACHS CEOCAST INC

Terra Energy & Resource Technologies, Inc. (OTCBB: TEGRE), an energy technology company that combines satellite-based technology with traditional exploration services, which does business through Terra Insight Corporation, its wholly owned subsidiary, announced that Terra Insight delivered its first stage STeP report on a 1,000,000 acre oil and gas exploration project in Eastern Turkey, pursuant to a service contract with Calik Enerji Sanayi ve Ticaret, A. S. The agreement provides for the company to receive a 20% working interest in the project, as well as undiscounted rates to be paid out of future returns of the project. Under the contract, Terra Insight is providing studies of the area of interest, for identification of prospective drilling sites and mapping of hydrocarbon anomalies using proprietary STeP technology. The company believes that the role of its STeP technology in the search for gas and oil, as well as other minerals, without depth limitations, will become increasingly recognizable to leading oil and gas exploration companies. Shares ended the week at $0.27, down $0.02.

MICHAEL WACHS CEOCAST NEWS

Pluristem Life Systems, Inc. (OTCBB: PLRS), a bio-therapeutics company dedicated to the commercialization of products for a variety of malignant, degenerative and auto-immune indications, reported that the company will present favorable results of pre-clinical studies of its proprietary PLacental eXpanded (PLX) cells for additional clinical indications next week at the 3rd World Congress on Regenerative Medicine in Leipzig, Germany. Recently, the company announced favorable results in pre-clinical testing of PLX cells to treat limb ischemia, and also showed in vitro to have properties that might give these cells the potential to treat Parkinson's Disease. Pluristem believes PLX cells can be used to treat other diseases, such as central nervous system and cardiovascular disorders as well, and is planning to submit the IND for its first product, PLX-I, for the treatment of blood cancers, to begin clinical trials early next year. Shares ended the week at $0.03, down one penny.

MICHAEL WACHS CEOCAST NEWS The stock has been volatile, reaching a 52-week high of $0.83 in late March. Today, it trades closer to its 52-week low of $0.08, although that could change as increased interest in stem cells as a result of the Democrats securing control of Congress has already lifted many stem cell stocks. Since the beginning of the year, shares of Stem Cells have rallied 25%, while Aastrom Biosciences has jumped 17%.While the debate over the use of stem cells will continue, for investors seeking an undiscovered way to participate in growing interest in this area, Stem Cell Innovations represents an undiscovered way to invest in the sector.

CEOCAST AND MICHAEL WACHS INTERVIEW

Read more: MICHAEL WACHS CEOCAST MICHAEL WACHS CEOCAST